Chronicmucocutaneous candidiasis is a rare genetic condition occurring in childhood that affects skin, nails and mucosal sites. It is characterised by persistent and widespreadcandidainfection. It is also called chronic mucocutaneous candidosis.
What causes chronic mucocutaneous candidiasis?
Chronic mucocutaneous candidiasis is due to primary immune deficiency. It is associated with various syndromes and laboratory abnormalities.
There is a genetic predisposition with either autosomal dominant inheritance (an abnormal gene inherited from one parent) or autosomal recessive inheritance (an abnormal gene inherited from each parent).
Autosomal dominant chronic mucocutaneous candidiasis is associated with gain-of-function STAT1mutations resulting in IL-17 deficiency.
Chronic mucocutaneous candidiasis is associated with certain endocrine conditions: hypoparathyroidism, hypothyroidism, hypoadrenalism, diabetes mellitus (autoimmune polyendocrinopathy type 1, or APECED syndrome, in which there is a mutation of the AIRE gene).
It is also associated with immune defects, include malfunctioning T lymphocytes and low levels of immunoglobulin.
Rarely, chronic mucocutaneous candidiasis develops in adult life. This is often as a result of a thymoma (tumour of the thymus gland) and is associated with internal diseases such as myasthenia gravis or myositis, or bone marrow defects such as aplastic anaemia, neutropenia and hypogammaglobulinaemia.
Treatment depends on repeated or prolonged courses of oral antifungal medications, often in higher doses than is normally necessary for candida infections. Oral antifungal medications used for chronic mucocutaneous candidiasis include:
Evaluation and treatment of associated endocrinopathies should be undertaken in consultation with an endocrinologist.
References
van de Veerdonk FL, Plantinga TS, Hoischen A, et al. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med. 2011 Jul 7. 365(1):54–61. PubMed.
Higgs JM. Chronic mucocutaneous candidiasis: iron deficiency and the effects of iron therapy. Proceedings of the Royal Society of Medicine. 1973;66(8):802–4. PubMedCentral.
Firinu D, Massidda O, Lorrai MM, Serusi L, Peralta M, Barca MP, Serra P, Manconi PE. Successful treatment of chronic mucocutaneous candidiasis caused by azole-resistant Candida albicans with posaconazole. Clin Dev Immunol. 2011;2011:283239. doi: 10.1155/2011/283239. Epub 2010 Dec 1. PubMed PMID: 21197459; PubMed Central PMCID: PMC3003968.
Mössner R, Diering N, Bader O, Forkel S, Overbeck T, Gross U, et al. Ruxolitinib Induces Interleukin 17 and Ameliorates Chronic Mucocutaneous Candidiasis Caused by STAT1 Gain-of-Function Mutation. Clin Infect Dis. 2016 Apr 1. 62 (7):951–3. PubMed.
Masi M, De Vinci C, Baricordi OR. Transfer factor in chronic mucocutaneous candidiasis. Biotherapy. 1996. 9(1-3):97–103. PubMed.
Rosa DD, Pasqualotto AC, Denning DW. Chronic mucocutaneous candidiasis and oesophageal cancer. Med Mycol. 2008 Feb;46(1):85–91. PubMed PMID: 17852718. PubMed.